How Accurate Is FIB-4 vs Fibroscan in Clinical Practice: Comparing Methodology of Liver Fibrosis Assessment

Document Type

Conference Proceeding

Publication Date

10-1-2024

Publication Title

Am J Gastroenterol

Abstract

Introduction: The associated risks of liver biopsy for assessing fibrosis in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) have heightened the need to validate non-invasive fibrosis scores for accuracy and efficacy. This study aims to compare the accuracy of the FIB-4 (Fibrosis-4) and Fibroscan scores in diagnosing fibrosis in MASLD patients. Methods: A total of 116 patients were categorized into 3 groups based on their Fibroscan kPa (kilopascal) scores: Group I with mild fibrosis (MF), comprising F0 to F1, and Group II with moderate fibrosis (AF), comprising F2-F3, with group 3 with advanced fibrosis classified as F4. Results: The study evaluated the correlations between Fibroscan, FIB-4 values and liver biopsy stage in various subgroups of patients. In the overall cohort (N=116), significant positive correlations were found between Fibroscan and liver biopsy stage (R=0.246, P=0.008), and liver biopsy stage and FIB-4 value (R=0.537, P<0.001). Among males (N=55), a strong significant correlation was observed between liver biopsy stage and FIB-4 value (R=0.727, P<0.001), though correlations involving Fibroscan were not significant. In females (N=61), significant positive correlations existed between all pairs of measures, with the strongest being between liver biopsy stage and FIB-4 value (R=0.349, P=0.006). Age-related analysis showed that in patients younger than 65 (N=82), significant correlations were found between Fibroscan and liver biopsy stage (R=0.332, P=0.002), and liver biopsy stage and FIB-4 value (R=0.602, P<0.001). For those aged 65 or older (N=34), only the correlation between liver biopsy stage and FIB-4 value was significant (R=0.390, P=0.023). Racial analysis revealed that in the White race group (N=89), significant correlations were found across all measures, while in the non-White group (N=25), only the correlation between liver biopsy stage and FIB-4 value was significant (R=0.706, P<0.001; Table 1). Conclusion: Both FIB-4 and Fibroscan can be used to rule out advanced fibrosis in MASLD patients. However, a stronger relationship between liver biopsy stage and FIB-4 value was noted compared to their individual associations with Fibroscan.

Volume

119

Issue

10

First Page

S1385

Find It @ Sladen

Share

COinS